CareDx

The firm intends to use the proceeds for working capital, general corporate purposes and the potential repayment of indebtedness.

The firm announced in October that had entered into an agreement with Jefferies to sell up to $50 million in shares from time to time.

The company said testing services revenues more than doubled during the quarter as its AlloSure kidney transplant diagnostic continued to penetrate the market.

The company said it intends to use the proceeds for working capital and corporate purposes, including capital expenditures, R&D, clinical trials, and more.

The company's shares grew 28 percent in September after it terminated a licensing deal with BioMérieux and regained control of certain intellectual property.

CareDx led the Index for the month — the firm's shares rose 81 percent on the strength of its second quarter earnings report.

The company also said it launched a new comprehensive diagnostic called HeartCare for surveillance of heart transplant patients.

The firm said momentum from the launch of its kidney transplant test Allosure drove the overall revenue increase.

CareDx has paid Illumina a $5 million initial payment and will pay royalties in the mid-single to low-double digits on sales of future commercialized products.

Pages

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.